Lars Sävendahl1, Effie Pournara2, Birgitte Tønnes Pedersen3, Oliver Blankenstein4. 1. Department of Women's and Children's HealthKarolinska Institutet and Pediatric Endocrinology Unit, Karolinska University Hospital, SE-171 76 Stockholm, Sweden. 2. Global Medical AffairsNovo Nordisk Health Care AG, 8050 Zurich, Switzerland. 3. Epidemiology, Novo Nordisk A/S2860 Søborg, Denmark. 4. Institute for Experimental Pediatric EndocrinologyCharité-University Medicine Berlin, 13353 Berlin, Germany.
Abstract
OBJECTIVE: Concerns have been raised of increased mortality risk in adulthood in certain patients who received growth hormone treatment during childhood. This study evaluated the safety of growth hormone treatment in childhood in everyday practice. DESIGN: NordiNet(®) International Outcome Study (IOS) is a noninterventional, observational study evaluating safety and effectiveness of Norditropin(®) (somatropin; Novo Nordisk A/S, Bagsvaerd, Denmark). METHODS: Long-term safety data (1998-2013) were collected on 13 834 growth hormone treated pediatric patients with short stature. Incidence rates (IRs) of adverse events (AEs) defined as adverse drug reactions (ADRs), serious ADRs (SADRs), and serious AEs (SAEs) were calculated by mortality risk group (low/intermediate/high). The effect of growth hormone dose on IRs and the occurrence of cerebrovascular AEs were investigated by the risk group. RESULTS: We found that 61.0% of patients were classified as low-risk, 33.9% intermediate-risk, and 5.1% high-risk. Three hundred and two AEs were reported in 261 (1.9%) patients during a mean (s.d.) treatment duration of 3.9 (2.8) years. IRs were significantly higher in the high- vs the low-risk group (high risk vs low risk-ADR: 9.11 vs 3.14; SAE: 13.66 vs 1.85; SADR: 4.97 vs 0.73 events/1000 patient-years of exposure; P < 0.0001 for all). Except for SAEs in the intermediate-risk group (P = 0.0486) in which an inverse relationship was observed, no association between IRs and growth hormone dose was found. No cerebrovascular events were reported. CONCLUSIONS: We conclude that safety data from NordiNet(®) IOS do not reveal any new safety signals and confirm a favorable overall safety profile in accordance with other pediatric observational studies. No association between growth hormone dose and the incidence of AEs during growth hormone treatment in childhood was found.
OBJECTIVE: Concerns have been raised of increased mortality risk in adulthood in certain patients who received growth hormone treatment during childhood. This study evaluated the safety of growth hormone treatment in childhood in everyday practice. DESIGN: NordiNet(®) International Outcome Study (IOS) is a noninterventional, observational study evaluating safety and effectiveness of Norditropin(®) (somatropin; Novo Nordisk A/S, Bagsvaerd, Denmark). METHODS: Long-term safety data (1998-2013) were collected on 13 834 growth hormone treated pediatric patients with short stature. Incidence rates (IRs) of adverse events (AEs) defined as adverse drug reactions (ADRs), serious ADRs (SADRs), and serious AEs (SAEs) were calculated by mortality risk group (low/intermediate/high). The effect of growth hormone dose on IRs and the occurrence of cerebrovascular AEs were investigated by the risk group. RESULTS: We found that 61.0% of patients were classified as low-risk, 33.9% intermediate-risk, and 5.1% high-risk. Three hundred and two AEs were reported in 261 (1.9%) patients during a mean (s.d.) treatment duration of 3.9 (2.8) years. IRs were significantly higher in the high- vs the low-risk group (high risk vs low risk-ADR: 9.11 vs 3.14; SAE: 13.66 vs 1.85; SADR: 4.97 vs 0.73 events/1000 patient-years of exposure; P < 0.0001 for all). Except for SAEs in the intermediate-risk group (P = 0.0486) in which an inverse relationship was observed, no association between IRs and growth hormone dose was found. No cerebrovascular events were reported. CONCLUSIONS: We conclude that safety data from NordiNet(®) IOS do not reveal any new safety signals and confirm a favorable overall safety profile in accordance with other pediatric observational studies. No association between growth hormone dose and the incidence of AEs during growth hormone treatment in childhood was found.
Authors: Cecilia Catellani; Gloria Ravegnini; Chiara Sartori; Beatrice Righi; Pietro Lazzeroni; Laura Bonvicini; Silvia Poluzzi; Francesca Cirillo; Barbara Predieri; Lorenzo Iughetti; Paolo Giorgi Rossi; Sabrina Angelini; Maria Elisabeth Street Journal: Front Endocrinol (Lausanne) Date: 2022-06-22 Impact factor: 6.055
Authors: Cheri Deal; Susan Kirsch; Jean-Pierre Chanoine; Sarah Lawrence; Elizabeth Cummings; Elizabeth T Rosolowsky; Seth D Marks; Nan Jia; Christopher J Child Journal: CMAJ Open Date: 2018-09-10
Authors: Christopher J Child; Alan G Zimmermann; George P Chrousos; Elisabeth Cummings; Cheri L Deal; Tomonobu Hasegawa; Nan Jia; Sarah Lawrence; Agnès Linglart; Sandro Loche; Mohamad Maghnie; Jacobo Pérez Sánchez; Michel Polak; Barbara Predieri; Annette Richter-Unruh; Ron G Rosenfeld; Diego Yeste; Tohru Yorifuji; Werner F Blum Journal: J Clin Endocrinol Metab Date: 2019-02-01 Impact factor: 5.958
Authors: Lars Sävendahl; Michel Polak; Philippe Backeljauw; Jo Blair; Bradley S Miller; Tilman R Rohrer; Alberto Pietropoli; Vlady Ostrow; Judith Ross Journal: J Clin Endocrinol Metab Date: 2019-10-01 Impact factor: 5.958
Authors: Lars Sävendahl; Michel Polak; Philippe Backeljauw; Joanne C Blair; Bradley S Miller; Tilman R Rohrer; Anita Hokken-Koelega; Alberto Pietropoli; Nicky Kelepouris; Judith Ross Journal: J Clin Endocrinol Metab Date: 2021-05-13 Impact factor: 5.958
Authors: Julia Anttonen; Tiina Remes; Pekka Arikoski; Päivi Lähteenmäki; Mikko Arola; Arja Harila-Saari; Tuula Lönnqvist; Tytti Pokka; Pekka Riikonen; Kirsti Sirkiä; Heikki Rantala; Marja Ojaniemi Journal: PLoS One Date: 2022-09-06 Impact factor: 3.752